ADIL
Adial Pharmaceuticals, Inc.
Set alert
5.05 USD +1.34 +36.12%
3.82 Day range 5.15
4.88 52-week range 5.05
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 3.83
- Prev close
- 3.71
- Mkt cap
- 13.26M
- Vol
- 83.08K
- Avg vol
- 57.15K
- EPS
- -20.65
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.82
- High
- 5.15
- Forward P/E
- -0.79
- Beta
- 1.30
- Short ratio
- 0.65
- Inst. own
- 3.03%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 1.06
- 200-d avg
- 1.23
- 1y target
- 7.50
Key statistics
- Market cap
- 6.73M
- Enterprise value
- 4.01M
- Trailing P/E
- 0.00
- Forward P/E
- -0.79
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.43
- EPS (TTM)
- -2.94
- Beta
- 1.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -2.99M
- Total cash
- 3.29M
- Total debt
- 0
- Return on equity
- -320.96%
- Shares outstanding
- 6.41M
- Short % of float
- 1.25%
- 50-day average
- 1.06
- 200-day average
- 1.23
Analyst view
Consensus: none
Price target (mean) 7.50 +48.5% upside
Now 5.05
- Target (low)
- 7.00
- Target (mean)
- 7.50
- Target (high)
- 8.00
Ratings (0m) 3 2 buy · 1 hold · 0 sell
- Strong buy0
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.33.
Financials — quick view
ADIL Revenue — quarterly 0
ADIL Net income — quarterly -51.99M
ADIL EPS — quarterly -11.25
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.50 | -0.38 | +0.12 | +24.00% |
| Aug 13, 2024 | Jun 1, 2024 | -0.39 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -0.39 | -0.59 | -0.20 | -51.28% |
| May 14, 2024 | Mar 1, 2024 | -0.51 | -0.68 | -0.17 | -33.33% |
| May 14, 2024 | Mar 1, 2024 | -0.51 | — | — | — |
| Apr 4, 2024 | Dec 1, 2023 | -0.89 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | Rodman & Renshaw | init | — | Buy |
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- adialpharma.com
News
- Adial Pharmaceuticals Plans To Change Corporate Name To Azora Therapeutics, Nasdaq Ticker to AZR, Effective Oct. 29
- Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
- Adial Pharmaceuticals Expects To Appoint Celia Economides As CFO At Its Annual Meeting, Succeeding Vinay Shah
- Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
- Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis
- Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on ADIL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CLAIBORNE CARY J | Chief Executive Officer | Stock Award(Grant) | May 22, 2023 | 1,520,000 |
| SCHUYLER KEVIN | Director | Purchase | Sep 28, 2023 | 6,589 |
| STILLEY WILLIAM B. III | Director | Stock Award(Grant) | May 22, 2023 | 1,261,780 |
| TRULUCK JOSEPH | Chief Financial Officer | Stock Award(Grant) | May 22, 2023 | 265,139 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Manchester Capital Management, LLC | 0.75% | 48,097 | 50.50K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.71% | 45,466 | 47.74K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.52% | 33,270 | 34.93K | Sep 29, 2024 |
| Blackrock Inc. | 0.43% | 27,770 | 29.16K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.42% | 27,115 | 28.47K | Sep 29, 2024 |
| UBS Group AG | 0.07% | 4,404 | 4.62K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.55% | 35,139 | 36.90K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.15% | 9,359 | 9.83K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.14% | 9,158 | 9.62K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.12% | 7,754 | 8.14K | Oct 30, 2024 |